Evidence Explorer / Evidence record
NUTRIENTS & SUPPLEMENTS
IV vitamin C in pancreatic cancer
Investigational randomized signal
Median survival was 16 months with pharmacological ascorbate plus chemotherapy versus 8.3 months with chemotherapy alone (HR 0.46; 90% CI 0.23–0.92).
MS-N003 · Sources checked October 11, 2026 · Cancer-control research
What was studied?
People and setting: Metastatic pancreatic cancer with gemcitabine/nab-paclitaxel
Evidence basis: Small randomized trial; 36 randomized, 34 treated
What can we conclude?
A small trial needs independent confirmation; it does not establish a cure. IV exposure is not reproduced by oral vitamin C.
Safety and practical context
Kidney disease, kidney stones and G6PD deficiency require particular attention; high-dose IV treatment needs specialist oversight.
Questions for the care team
- Does this evidence apply to my cancer, treatment and goal?
- Does the exact preparation or delivery method match the study?
- What benefit is plausible, what could go wrong, and what care must continue?
Sources
Connected reviews
Learn how to judge a study · Return to the evidence map
This is a concise evidence brief, not an exhaustive systematic review or a personal treatment recommendation. Evidence labels describe the named use; they are not formal GRADE ratings. A missing harm report does not establish safety.
